MCID: THR024
MIFTS: 54

Thrombosis

Categories: Blood diseases, Cardiovascular diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Thrombosis

MalaCards integrated aliases for Thrombosis:

Name: Thrombosis 11 53 43 14 71
Thrombosis of Blood Vessel 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0060903
MeSH 43 D013927
UMLS 71 C0040053 C2586211

Summaries for Thrombosis

Disease Ontology: 11 A vascular disease caused by the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.

MalaCards based summary: Thrombosis, also known as thrombosis of blood vessel, is related to thrombophilia due to thrombin defect and cavernous sinus thrombosis. An important gene associated with Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Metabolism of proteins and Signal Transduction. The drugs Dabigatran and Norethisterone have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and heart, and related phenotypes are no effect and no effect

Related Diseases for Thrombosis

Diseases related to Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2507)
# Related Disease Score Top Affiliating Genes
1 thrombophilia due to thrombin defect 33.2 VWF THBD SERPINC1 PROC PLAT FGA
2 cavernous sinus thrombosis 33.1 SERPINC1 F3 F2
3 portal vein thrombosis 33.1 VWF THBD SERPINC1 PLG JAK2 F5
4 coronary thrombosis 33.0 VWF SERPINC1 PLG PLAT GP1BA FGA
5 intracranial thrombosis 32.9 VWF SERPINC1 PLG PLAT FGA F5
6 sagittal sinus thrombosis 32.8 SERPINC1 PLG JAK2 F5 F3 F2
7 lateral sinus thrombosis 32.8 SERPINC1 F2
8 heparin-induced thrombocytopenia 32.7 F3 F2
9 carotid artery thrombosis 32.7 VWF SERPINC1 PLG PLAT GP1BA F3
10 budd-chiari syndrome 32.7 VWF SERPINC1 PLG JAK2 FGB F5
11 essential thrombocythemia 32.6 VWF THBD PLAT JAK2 GP1BA
12 intracranial sinus thrombosis 32.5 SERPINC1 PLG F3 F2 APOH
13 antiphospholipid syndrome 32.5 VWF THBD TFPI SERPINC1 PLAT GP1BA
14 antithrombin iii deficiency 32.5 SERPINC1 PLG JAK2 FGA F5 F3
15 cerebral sinovenous thrombosis 32.5 F5 F2
16 pulmonary embolism 32.5 VWF THBD SERPINC1 PROS1 PROC PLAT
17 thrombophilia due to activated protein c resistance 32.4 VWF THBD SERPINC1 PLG F9 F5
18 protein s deficiency 32.4 THBD SERPINC1 PROS1 PROC FGA F5
19 buerger disease 32.4 SERPINC1 F2 APOH
20 post-thrombotic syndrome 32.4 VWF THBD TFPI SERPINC1 PLG PLAT
21 protein c deficiency 32.4 THBD SERPINC1 PROC F9 F5 F2
22 vascular disease 32.3 VWF THBD SERPINC1 PLAT GP1BA FGB
23 polycythemia vera 32.3 VWF THBD SERPINC1 JAK2 GP1BA F5
24 dysfibrinogenemia, congenital 32.3 THBD SERPINC1 PLAT FGG FGB FGA
25 shwartzman phenomenon 32.3 SERPINA10 F3
26 coumarin resistance 32.3 PROS1 F9 F2
27 hyperhomocysteinemia 32.2 VWF THBD SERPINC1 PLAT F5 F2
28 homocysteinemia 32.2 F5 F2
29 thrombophilia 32.1 VWF THBD TFPI SERPINC1 SERPINA10 PROS1
30 hepatic veno-occlusive disease 32.1 THBD SERPINC1 PLG PLAT F3
31 chronic venous insufficiency 32.1 VWF SERPINC1 PLG F3 F2
32 factor vii deficiency 32.1 SERPINC1 F9 F3 F2
33 moyamoya disease 1 32.1 VWF SERPINC1 PLG PLAT F3 F2
34 varicose veins 32.0 VWF THBD SERPINC1 PLAT F5 F2
35 factor v deficiency 32.0 VWF SERPINC1 F9 F5 F3 F2
36 vitamin k deficiency bleeding 32.0 SERPINC1 PROS1 F9 F3 F2
37 central retinal vein occlusion 32.0 SERPINC1 PLG PLAT F5 F3 F2
38 cardiovascular system disease 31.9 VWF THBD SERPINC1 PLG PLAT FGA
39 systemic lupus erythematosus 31.9 VWF THBD SERPINC1 PLG F3 F2
40 livedoid vasculitis 31.9 SERPINC1 PLG F3 F2 APOH
41 polycythemia 31.8 JAK2 F5 F3 F2
42 factor viii deficiency 31.8 VWF TFPI SERPINC1 F9 F5 F3
43 nephrotic syndrome 31.8 SERPINC1 PLG FGA F9 F3 F2
44 heparin cofactor ii deficiency 31.7 SERPINC1 PLG
45 thrombocytopenia 31.7 VWF THBD SERPINC1 PROS1 PROC PLAT
46 behcet syndrome 31.7 VWF THBD SERPINC1 JAK2 F5 F3
47 venous insufficiency 31.7 VWF PLAT F5 F2
48 stroke, ischemic 31.7 VWF THBD SERPINC1 PLG PLAT GP1BA
49 thrombophlebitis 31.7 VWF SERPINC1 PROS1 PROC PLG PLAT
50 intracranial hypertension 31.7 SERPINC1 PLG F9 F5 F3 F2

Graphical network of the top 20 diseases related to Thrombosis:



Diseases related to Thrombosis

Symptoms & Phenotypes for Thrombosis

GenomeRNAi Phenotypes related to Thrombosis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 APOH F13A1 F2 F3 F5 F9
2 no effect GR00402-S-2 10.18 APOH F13A1 F2 F3 F5 F9

MGI Mouse Phenotypes related to Thrombosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 APOH F13A1 F2 F3 F5 F9
2 nervous system MP:0003631 10.32 F2 F3 F5 FGA JAK2 PLAT
3 cardiovascular system MP:0005385 10.32 F13A1 F2 F3 F5 F9 FGA
4 immune system MP:0005387 10.13 F2 F3 F9 FGA FGG JAK2
5 liver/biliary system MP:0005370 10.11 F5 F9 FGA JAK2 PLG PROC
6 embryo MP:0005380 10.1 F2 F3 F5 F9 FGA FGG
7 hematopoietic system MP:0005397 10.06 F13A1 F2 F3 F9 FGA FGB
8 mortality/aging MP:0010768 9.93 APOH F13A1 F2 F3 F5 F9
9 respiratory system MP:0005388 9.91 F13A1 F2 F3 FGG JAK2 PLAT
10 integument MP:0010771 9.36 F13A1 F2 F3 F5 FGA JAK2

Drugs & Therapeutics for Thrombosis

Drugs for Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 375)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabigatran Approved, Investigational Phase 4 211914-51-1 216210
2
Norethisterone Approved Phase 4 68-22-4 199472 6230
3
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
4
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
5
Tranylcypromine Approved, Investigational Phase 4 155-09-9 5530 441233
6
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
7
Abciximab Approved Phase 4 143653-53-6 3815015
8
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
9
Polyestradiol phosphate Approved Phase 4 28014-46-2
10
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
11
Fluindione Approved, Investigational Phase 4 957-56-2
12
Phenindione Approved, Investigational Phase 4 83-12-5 4760
13
Acetaminophen Approved Phase 4 103-90-2 1983
14
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
15 Orange Approved Phase 4
16
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
17
Taurolidine Approved, Investigational Phase 4 19388-87-5
18
Glimepiride Approved Phase 4 93479-97-1 3476
19
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
20
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
21
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
22
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
23
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
24
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
25
Ticagrelor Approved Phase 4 274693-27-5 9871419
26
Dipyridamole Approved Phase 4 58-32-2 3108
27
Pancrelipase Approved, Investigational Phase 4 53608-75-6 8519
28
Dronedarone Approved Phase 4 141626-36-0 208898
29
Erythromycin Approved, Investigational, Vet_approved Phase 4 55-31-2, 114-07-8 12560
30
Glucosamine Approved, Investigational Phase 4 3416-24-8 318324 439213
31
Ketoconazole Approved, Investigational Phase 4 65277-42-1, 142128-57-2 47576 3823 638701
32
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239
33
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
34
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
35
Apixaban Approved Phase 4 503612-47-3 10182969
36
Reviparin Approved, Investigational Phase 4 9041-08-1
37
Rivaroxaban Approved Phase 4 366789-02-8 9875401
38
Plasminogen Approved Phase 4 9001-91-6
39
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
40
Fondaparinux Approved, Investigational Phase 4 114870-03-0, 104993-28-4 5282448 636380
41
Desirudin Approved Phase 4 120993-53-5 16129703
42
Argatroban Approved, Investigational Phase 4 74863-84-6 152951 92722
43
Garlic Approved, Nutraceutical Phase 4 8008-99-9
44
Batroxobin Experimental Phase 4 9039-61-6
45
Coumarin Experimental Phase 4 91-64-5 323
46
Arachidonic Acid Experimental Phase 4 506-32-1 444899
47
Chlorotrianisene Investigational, Withdrawn Phase 4 569-57-3 11289
48
Norethindrone Acetate Phase 4 541197
49 Vasodilator Agents Phase 4
50 Anesthetics Phase 4

Interventional clinical trials:

(show top 50) (show all 1380)
# Name Status NCT ID Phase Drugs
1 Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs Unknown status NCT00450645 Phase 4 low molecular weight heparin
2 Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial Unknown status NCT01021488 Phase 4 Rosuvastatin 20mg/d for 14days;enoxaparin only
3 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
4 Dose Effect of Tranexamic Acid on the Incidence of Deep Venous Thrombus in Cardiac Surgery With Cardiopulmonary Bypass Unknown status NCT03838328 Phase 4 Tranexamic Acid
5 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
6 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
7 Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Undergoing Total Knee Replacement Arthroplasty: RE-STOP-DVT Study- A Prospective Randomized Controlled Trial Unknown status NCT01063426 Phase 4 High dose Atorvastatin+enoxaparin;Enoxaparin
8 The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis Unknown status NCT04269954 Phase 4 Batroxobin combined with low molecular weight heparin
9 The Efficacy and Safety of Prophylactic Anticoagulation for Catheter-related Thrombosis in Patients With Cancer and Implantable Venous Access Ports: a Prospective Multi-center Randomized Controlled Trial. Unknown status NCT04256525 Phase 4 Rivaroxaban 10mg;Aspirin 100mg;low molecule heparin
10 Patient Adherence to Venous Thromboembolism Prophylaxis in Orthopaedic Trauma Patients: A Randomized, Controlled Trial Comparing Subcutaneous Enoxaparin & Oral Rivaroxaban Unknown status NCT04169269 Phase 4 Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters;Rivaroxaban 10 milligram Oral Tablet
11 Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Unknown status NCT00640731 Phase 4
12 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
13 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
14 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
15 The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism. Unknown status NCT03129555 Phase 4 Dabigatran Etexilate Oral Capsule;Rivaroxaban Oral Tablet;Edoxaban Oral Tablet;Apixaban Oral Tablet
16 Single-blind, Randomized Comparison of Warfarin Management Guided by NextDose Versus Management Based on Clinician Experience. Unknown status NCT04510805 Phase 4
17 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
18 Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access Unknown status NCT04489849 Phase 4 Apixaban 2.5 MG
19 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
20 anti10a Levels in Women Treated With LMWH in the Postpartum Period for Preventing Vein Thrombosis Events: A Comparison of Two Doses Unknown status NCT02856295 Phase 4 clexane (LMWH)
21 Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Unknown status NCT01970280 Phase 4 Enoxaparin
22 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
23 Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline
24 RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib) Unknown status NCT03178656 Phase 4 Sorafenib
25 Taurolidine Citrate and Unfractionated Heparin Combination Versus Unfractionated Heparin Alone in Prevention of Inflammation in Hemodialysis Catheters. Unknown status NCT03539718 Phase 4 Taurolidine heparin;Heparin Sodium
26 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
27 a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
28 Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers Unknown status NCT01478282 Phase 4 Rivaroxaban;Dabigatran
29 A Randomised Controlled Trial Comparing Bacteraemia Rates in Closed Luer Lock Access Devices(TEGO) With Standard Devices in the Outpatient Haemodialysis Population Unknown status NCT01082770 Phase 4
30 Impact of a Biological Glue (Evicel®) on the Peri Operative Bleeding in Total Knee Prothesis Surgery Unknown status NCT00983112 Phase 4 Human Fibrinogen and human thrombin (Evicel);Sodium Chlorure (Physiological saline)
31 A Multi-center Randomized Controlled Study of High/Low-dosage Rivaroxaban Compared With DAPT After Left Atrial Appendage Occulsion in Patients With Non-valvular Atrial Fibrillation(ESCORT-AF Study) Unknown status NCT04135677 Phase 4 Rivaroxaban;DAPT
32 Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery Unknown status NCT00733434 Phase 4 Prostaglandin E1
33 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
34 Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial Unknown status NCT01670474 Phase 4 rt-PA (2mg/2mL) actilysis;rt-PA
35 Phase 4 Study of Primary Angioplasty Combined Distal Injection of Abciximab to Thrombus and Aspiration With Catheter Unknown status NCT01383785 Phase 4
36 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II) Unknown status NCT01013038 Phase 4
37 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial Unknown status NCT01350206 Phase 4
38 A Multi-center Study on the Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus. Unknown status NCT03415386 Phase 4 Combination of antiplatelet drugs and anticoagulants for at least one month
39 Treatment of Upper Extremity Deep-Vein Thrombosis Completed NCT00245856 Phase 4 Dalteparin sodium injection;Warfarin
40 Absence of Residual Vein Thrombosis After an Episode of Unprovoked Deep Vein Thrombosis: Short-Term Anticoagulation is Safe. Completed NCT00623987 Phase 4 warfarin accordingly INR value
41 Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs Completed NCT00438230 Phase 4 Warfarin
42 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4
43 A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study) Completed NCT00203580 Phase 4 Tinzaparin sodium
44 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE Completed NCT04373707 Phase 4 Enoxaparin
45 Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism Completed NCT00365950 Phase 4 Duration of anticoagulation;Warfarin duration
46 Echo-Doppler Assessment of the Occurrence of Asymptomatic Deep Vein Thrombosis (DVT) in Orthopedic Replacement Surgery Under Enoxaparine (PRENOXA) Completed NCT01354704 Phase 4 Enoxaparin
47 LITE Study, Appendix A (HOME-LITE), Amendment 6 Completed NCT00203658 Phase 4 Tinzaparin sodium
48 A Pilot Study in Cancer Patients With Central Venous Catheter Associated Deep Vein Thrombosis in the Upper Extremity Treated With Rivaroxaban (Catheter 2) Completed NCT01708850 Phase 4 Rivaroxaban
49 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
50 Prospective, Randomized, Double-blinded Trial of the Efficacy and Safety of Different Doses and Duration of Low Molecular Weight Heparin (Dalteparin) in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin

Search NIH Clinical Center for Thrombosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentoxifylline

Cochrane evidence based reviews: thrombosis

Genetic Tests for Thrombosis

Anatomical Context for Thrombosis

Organs/tissues related to Thrombosis:

MalaCards : Liver, Endothelial, Heart, Whole Blood, Brain, Neutrophil, Lung

Publications for Thrombosis

Articles related to Thrombosis:

(show top 50) (show all 31037)
# Title Authors PMID Year
1
Clinical experience with alteplase in the management of intracardiac and major cardiac vessels thrombosis in pediatrics: a case series. 53 62
20427940 2010
2
Persistency of low levels of anticardiolipin and anti-beta2 glycoprotein1 in thrombosis. 53 62
20206880 2010
3
Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. 53 62
19640573 2010
4
Acute mesenteric and aortic thrombosis associated with antithrombin deficiency: a rare occurrence. 53 62
19932950 2010
5
Emerging roles of fibronectin in thrombosis. 53 62
20116835 2010
6
Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. 53 62
20445954 2010
7
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 53 62
20004006 2010
8
P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. 53 62
20473398 2010
9
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. 53 62
20353989 2010
10
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. 53 62
19883911 2010
11
Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release. 53 62
20087632 2010
12
Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients. 53 62
19497612 2010
13
Continuous intraarterial thrombolysis for early hepatic artery thrombosis following liver transplantation: case report. 53 62
20034941 2010
14
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. 53 62
19582452 2010
15
JAK2 mutation and thrombosis in the myeloproliferative neoplasms. 53 62
20425393 2010
16
Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. 53 62
19398123 2010
17
ABO blood groups and genetic risk factors for thrombosis in Croatian population. 53 62
20017223 2009
18
Thrombosis markers in hip versus knee arthroplasty: a pilot study. 53 62
20065366 2009
19
Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34(+) cells are functionally active in an ex vivo flow model of thrombosis. 53 62
19741191 2009
20
Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations. 53 62
19067121 2009
21
Prevalence of factor V leiden mutation in patients with thrombosis in Tunisia. 53 62
20218141 2009
22
Study on the changes of thrombosis-associated factors in patients with coronary heart disease of turbidity-phlegm blocking syndrome. 53 62
19802536 2009
23
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. 53 62
19214510 2009
24
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. 53 62
19195685 2009
25
Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy. 53 62
19476973 2009
26
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 53 62
19660606 2009
27
Bilateral cavo-ilio-femoral thrombosis in an adolescent with transient anti-phospholipid antibodies and factor V heterozygous mutation: a case report. 53 62
19918549 2009
28
Assessing the coagulation factor levels, inherited thrombophilia, and ABO blood group on the risk for venous thrombosis among Brazilians. 53 62
19398413 2009
29
Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. 53 62
19421222 2009
30
Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis. 53 62
19481472 2009
31
Thr715Pro P-selectin polymorphism and P-selectin release in blood obtained from the bleeding time wounds in patients with deep-vein thrombosis. 53 62
19106004 2009
32
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. 53 62
19414836 2009
33
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. 53 62
19193675 2009
34
Markers of thrombosis and hemostasis in acute coronary syndromes: relationship to increased heart rate and reduced heart-rate variability. 53 62
19353696 2009
35
Autoantibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis. 53 62
19192108 2009
36
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. 53 62
19268736 2009
37
The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. 53 62
19353312 2009
38
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. 53 62
19105233 2009
39
Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation. 53 62
19193009 2009
40
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. 53 62
19180123 2009
41
Successful management of multiple permanent pacemaker complications--infection, 13 year old silent lead perforation and exteriorisation following failed percutaneous extraction, superior vena cava obstruction, tricuspid valve endocarditis, pulmonary embolism and prosthetic tricuspid valve thrombosis. 53 62
19239701 2009
42
Role of pulsatile perfusion with tissue plasminogen activator in deceased donor kidneys with extensive glomerular thrombosis. 53 62
19249467 2009
43
Calumenin but not reticulocalbin forms a Ca2+-dependent complex with thrombospondin-1. A potential role in haemostasis and thrombosis. 53 62
18688696 2009
44
JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease. 53 62
19478480 2009
45
The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis. 53 62
18682947 2009
46
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. 53 62
18954937 2008
47
Mitogen-activated protein kinases in hemostasis and thrombosis. 53 62
18826389 2008
48
Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass. 53 62
18575842 2008
49
Acute left atrial thrombosis during anticoagulant therapy in a patient with antithrombin deficiency. 53 62
19014009 2008
50
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). 53 62
18539899 2008

Variations for Thrombosis

Expression for Thrombosis

Search GEO for disease gene expression data for Thrombosis.

Pathways for Thrombosis

Pathways related to Thrombosis according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 SERPINC1 SERPINA10 PROS1 PROC PLG FGG
2 13.68 F2 F3 FGA FGB FGG JAK2
3
Show member pathways
13.3 APOH F13A1 F2 F3 F5 F9
4
Show member pathways
12.73 JAK2 FGG FGB FGA F2
5
Show member pathways
12.65 VWF PLG FGG FGB FGA
6
Show member pathways
12.6 PROS1 PLG FGG FGB FGA F2
7
Show member pathways
12.58 VWF JAK2 FGG FGB FGA
8
Show member pathways
12.54 F13A1 F2 F3 F5 F9 FGA
9
Show member pathways
12.47 F13A1 F2 F3 F5 F9 FGA
10
Show member pathways
12.34 SERPINC1 SERPINA10 PROC PLG FGG FGA
11
Show member pathways
12.32 FGG FGB FGA F13A1
12
Show member pathways
12.14 THBD PROS1 PROC F2
13
Show member pathways
12.11 FGA FGB FGG VWF
14
Show member pathways
12.11 VWF JAK2 FGG FGB FGA
15
Show member pathways
11.89 PROS1 PROC F9 F2
16
Show member pathways
11.86 VWF GP1BA FGG FGB FGA F2
17 11.58 VWF FGG FGB FGA F2
18 11.54 FGA FGB FGG PLAT PLG
19 11.46 PLG PLAT FGG FGB FGA
20 11.42 FGA FGB FGG PLG
21 11.33 FGG FGB FGA
22
Show member pathways
11.33 PROS1 PROC F9 F2
23 11.26 FGA FGB FGG GP1BA PLAT PROC
24 11.23 TFPI PLG F2
25 10.74 PLG PLAT
26 9.95 F13A1 F2 FGA FGB FGG PLG

GO Terms for Thrombosis

Cellular components related to Thrombosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.61 APOH F2 F9 FGA FGB FGG
2 extracellular region GO:0005576 10.53 APOH F13A1 F2 F3 F5 F9
3 cell surface GO:0009986 10.4 APOH F3 FGA FGB FGG GP1BA
4 endoplasmic reticulum lumen GO:0005788 10.34 F2 F5 F9 FGA FGG PROC
5 external side of plasma membrane GO:0009897 10.29 THBD GP1BA FGG FGB FGA F3
6 blood microparticle GO:0072562 10.16 F13A1 F2 FGA FGB FGG PLG
7 Golgi lumen GO:0005796 10.13 PROS1 PROC F9 F2
8 platelet alpha granule GO:0031091 10.07 VWF FGG FGB FGA F5
9 serine-type endopeptidase complex GO:1905370 10.06 THBD PROC F9 F2
10 platelet alpha granule lumen GO:0031093 10.06 VWF PROS1 PLG FGG FGB FGA
11 collagen-containing extracellular matrix GO:0062023 10.02 APOH F13A1 F2 F3 F9 FGA
12 fibrinogen complex GO:0005577 9.95 FGG FGB FGA
13 extracellular space GO:0005615 9.9 APOH F13A1 F2 F3 F5 F9

Biological processes related to Thrombosis according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 10.4 F2 F9 PLAT PLG PROC THBD
2 blood coagulation GO:0007596 10.37 F13A1 F2 F3 F5 F9 FGA
3 negative regulation of endopeptidase activity GO:0010951 10.22 TFPI SERPINC1 SERPINA10 PROS1
4 response to calcium ion GO:0051592 10.11 FGG FGB FGA
5 platelet aggregation GO:0070527 10.11 GP1BA FGG FGB FGA
6 positive regulation of protein secretion GO:0050714 10.09 FGG FGB FGA
7 platelet activation GO:0030168 10.09 VWF GP1BA FGG FGB FGA F2
8 positive regulation of substrate adhesion-dependent cell spreading GO:1900026 10.08 FGG FGB FGA
9 negative regulation of endothelial cell apoptotic process GO:2000352 10.07 FGA FGB FGG
10 positive regulation of vasoconstriction GO:0045907 10.05 FGG FGB FGA
11 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 10.04 FGG FGB FGA
12 positive regulation of exocytosis GO:0045921 10.03 FGG FGB FGA
13 negative regulation of blood coagulation GO:0030195 10.02 APOH PROC PROS1 TFPI THBD
14 negative regulation of fibrinolysis GO:0051918 10.02 THBD PLG PLAT F2 APOH
15 protein polymerization GO:0051258 10.01 FGA FGB FGG
16 blood coagulation, fibrin clot formation GO:0072378 10.01 FGG FGB FGA F13A1
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 10 FGG FGB FGA
18 positive regulation of peptide hormone secretion GO:0090277 9.97 FGG FGB FGA
19 plasminogen activation GO:0031639 9.96 APOH FGA FGB FGG PLAT
20 regulation of blood coagulation GO:0030193 9.95 APOH F2 GP1BA SERPINC1
21 positive regulation of platelet activation GO:0010572 9.94 JAK2 GP1BA
22 negative regulation of platelet activation GO:0010544 9.94 THBD F2
23 blood coagulation, intrinsic pathway GO:0007597 9.93 GP1BA APOH
24 induction of bacterial agglutination GO:0043152 9.91 FGB FGA
25 hemostasis GO:0007599 9.91 F13A1 F2 F3 F5 F9 FGA
26 trans-synaptic signaling by BDNF, modulating synaptic transmission GO:0099183 9.88 PLG PLAT
27 blood coagulation, common pathway GO:0072377 9.85 THBD FGA
28 regulation of body fluid levels GO:0050878 9.76 PROC F9 F5 F2
29 fibrinolysis GO:0042730 9.53 F2 FGA FGB FGG GP1BA PLAT

Molecular functions related to Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 10 F2 FGA FGB FGG JAK2 PLAT
2 heparin binding GO:0008201 9.97 SERPINC1 SERPINA10 F2 APOH
3 extracellular matrix structural constituent GO:0005201 9.86 VWF FGG FGB FGA
4 peptidase activity GO:0008233 9.72 PROC PLG PLAT F9 F2
5 serine-type peptidase activity GO:0008236 9.43 PROC PLG PLAT F9 F2
6 serine-type endopeptidase activity GO:0004252 9.4 PROC PLG PLAT F9 F3 F2

Sources for Thrombosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....